$\square$ 

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

## OMB APPROVAL OMB Number: 3235-0287

Estimated average burden	
hours per response:	0.5

		Person <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Aquestive Therapeutics, Inc.</u> [ AQST ]		tionship of Reporting Pe all applicable) Director	rson(s) to Issuer 10% Owner
(1 +)	( <b>F</b> ire t)	( <b>N</b> 4) - 1 - 1 - 1	3. Date of Earliest Transaction (Month/Dav/Year)	X	Officer (give title below)	Other (specify below)
(Last)	(First)	(Middle)	02/28/2019		SVP-Operations/Va	alue Delivery
C/O AQUESTIVE THERAPEUTICS, INC.			02/28/2019		ovi operations, ve	inde Denvery
<b>30 TECHNOL</b>	OGY DRIVE					
			4. If Amendment, Date of Original Filed (Month/Day/Year)		ridual or Joint/Group Filin	ng (Check Applicable
(Street)				Line)		
WARREN	NJ	07059		X	Form filed by One Rep	porting Person
, WARKEN	INJ	07039			Form filed by More that Person	an One Reporting
(City)	(State)	(Zip)				

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

ſ	1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
				Code	v	Amount	(A) or (D)	Price	<ul> <li>Reported Transaction(s) (Instr. 3 and 4)</li> </ul>		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (II 3, 4 and	ve es d ed nstr.	6. Date Exerc Expiration Da (Month/Day/Y	ite	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- Qualified Stock Option (right to buy)	\$8.05	02/28/2019		A		30,000		(1)	02/28/2029	Common Stock	30,000	\$ <u>0</u>	30,000	D	

Explanation of Responses:

1. The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries.

### **Remarks:**

/s/ Robert Arnold, as Attorney-03/04/2019 In-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.